var data={"title":"Fidaxomicin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fidaxomicin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/472870?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fidaxomicin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fidaxomicin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13120424\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dificid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14732997\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dificid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12861920\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Macrolide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923821\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Treatment of diarrhea due to </b> <b><i>Clostridium difficile </i></b> <b>(CDAD):</b> Oral: 200 mg twice daily for 10 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923822\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923834\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary (minimal systemic absorption).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923835\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s label (has not been studied); However, due to minimal systemic absorption no dosage adjustment predicted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13120425\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dificid: 200 mg [contains soybean lecithin]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923550\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923824\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered with or without food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12861917\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of <i>Clostridium difficile</i>-associated diarrhea (CDAD)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923672\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Nausea (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">2% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal hemorrhage (4%), abdominal pain, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (2%), neutropenia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;2%, postmarketing, and/or case reports: Abdominal distention, abdominal tenderness, angioedema, decreased platelet count, decreased serum bicarbonate, dyspepsia, dysphagia, dyspnea, fixed drug eruption, flatulence, hepatotoxicity (idiosyncratic) (Chalasani, 2014), hyperglycemia, hypersensitivity reaction, increased liver enzymes, increased serum alkaline phosphatase, intestinal obstruction, megacolon, metabolic acidosis, pruritus, skin rash</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923669\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to fidaxomicin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923670\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (angioedema [mouth, face, throat], dyspnea, pruritus, and rash) to fidaxomicin have been reported.  If a severe reaction occurs, discontinue drug and institute supportive care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Macrolide allergy: Use with caution in patients with a history of macrolide allergy; may be at increased risk for hypersensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do not use for systemic infections; fidaxomicin systemic absorption is negligible. Use only in patients with proven or strongly suspected <i>Clostridium difficile (C. difficile) </i>infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299334\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12931805\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16497&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: Macrolide Antibiotics may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923666\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923667\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Due to the limited systemic absorption of fidaxomicin, exposure to the fetus is expected to be low. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16355080\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if fidaxomicin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering fidaxomicin to nursing women. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923775\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits RNA polymerase sigma subunit resulting in inhibition of protein synthesis and cell death in susceptible organisms including <i>C. difficile</i>; bactericidal</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923777\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Minimal systemic absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Largely confined to the gastrointestinal tract; in single- and multiple-dose studies, fecal concentrations of fidaxomicin and its active metabolite (OP-1118) are very high while serum concentrations are minimally detectable to undetectable</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Intestinal hydrolysis to less active metabolite (OP-1118)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (&gt;92% as unchanged drug and metabolites); urine (&lt;1% as metabolite)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322903\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Dificid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (20): $4,417.92</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059491\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dificid (AU, BB, NZ);</li>\n      <li>Dificlir (AT, CY, CZ, DE, DK, EE, ES, FR, GB, HR, HU, IE, IL, IS, LT, LU, LV, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR);</li>\n      <li>Dyfiklir (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fidaxomicin-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen SH, Gerding DN, Johnson S, et al, &quot;Clinical Practice Guidelines for <i>Clostridium difficile</i> Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA),&quot; <i>Infect Control Hosp Epidemiol</i>, 2010, 31(5):431-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fidaxomicin-drug-information/abstract-text/20307191/pubmed\" target=\"_blank\" id=\"20307191\">20307191</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dificid (fidaxomicin) [prescribing information] Whitehouse Station, NJ: Merck; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Louie TJ, Emery J, Krulicki W, et al, &quot;OPT-80 Eliminates <i>Clostridium difficile</i> and Is Sparing of Bacteroides Species During Treatment of <i>C. difficile</i> Infection,&quot; <i>Antimicrob Agents Chemother</i>, 2009, 53(1):261-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fidaxomicin-drug-information/abstract-text/18955523/pubmed\" target=\"_blank\" id=\"18955523\">18955523</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Louie TJ, Miller MA, Crook DW, et al, &quot;Effect of Age on Treatment Outcomes in <i>Clostridium difficile</i> Infection,&quot; <i>J Am Geriatr Soc</i>, 2013, 61(2):222-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fidaxomicin-drug-information/abstract-text/23379974/pubmed\" target=\"_blank\" id=\"23379974\">23379974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Louie TJ, Miller MA, Mullane KM, et al, &quot;Fidaxomicin Versus Vancomycin for <i>Clostridium difficile</i> Infection,&quot; <i>N Engl J Med</i>, 2011, 364(5):422-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fidaxomicin-drug-information/abstract-text/21288078/pubmed\" target=\"_blank\" id=\"21288078\">21288078</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Louie T, Miller M, Donskey C, et al, &quot;Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial With Patients With <i>Clostridium difficile</i> Infection,&quot; <i>Antimicrob Agents Chemother</i>, 2009, 53(1):223-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fidaxomicin-drug-information/abstract-text/18955525/pubmed\" target=\"_blank\" id=\"18955525\">18955525</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shue YK, Sears PS, Shangle S, et al, &quot;Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers Following Single and Multiple Oral Doses,&quot; <i>Antimicrob Agents Chemother</i>, 2008, 52(4):1391-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fidaxomicin-drug-information/abstract-text/18268081/pubmed\" target=\"_blank\" id=\"18268081\">18268081</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sullivan KM and Spooner LM, &quot;Fidaxomicin: A Macrocyclic Antibiotic for the Management of <i>Clostridium difficile</i> Infection,&quot; <i>Ann Pharmacother</i>, 2010, 44(2):352-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fidaxomicin-drug-information/abstract-text/20071495/pubmed\" target=\"_blank\" id=\"20071495\">20071495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Surawicz CM, Brandt LJ, Binion DG, et al, &quot;Guidelines for Diagnosis, Treatment, and Prevention of <i>Clostridium difficile</i> Infections,&quot; <i>Am J Gastroenterol</i>, 2013, 108(4):478-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fidaxomicin-drug-information/abstract-text/23439232/pubmed\" target=\"_blank\" id=\"23439232\">23439232</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tannock GW, Munro K, Taylor C, et al, &quot;A New Macrocyclic Antibiotic, Fidaxomicin (OPT-80), Causes Less Alteration to the Bowel Microbiota of <i>Clostridium difficile</i>-Infected Patients Than Does Vancomycin,&quot; <i>Microbiology</i>, 2010, 156(Pt 11):3354-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fidaxomicin-drug-information/abstract-text/20724385/pubmed\" target=\"_blank\" id=\"20724385\">20724385</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16497 Version 87.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F13120424\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14732997\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F12861920\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F12923821\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F12923822\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F12923834\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F12923835\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F13120425\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F12923550\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F12923824\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F12861917\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F12923672\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F12923669\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F12923670\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299334\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F12931805\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F12923666\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F12923667\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16355080\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F12923775\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F12923777\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322903\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059491\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16497|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fidaxomicin-patient-drug-information\" class=\"drug drug_patient\">Fidaxomicin: Patient drug information</a></li></ul></div></div>","javascript":null}